Silver Oak Securities Incorporated Invests $220,000 in AtriCure, Inc. (NASDAQ:ATRC)

Silver Oak Securities Incorporated bought a new stake in AtriCure, Inc. (NASDAQ:ATRC) during the fourth quarter, Holdings Channel reports. The firm bought 7,278 shares of the medical device company’s stock, valued at approximately $220,000.

Other institutional investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its holdings in shares of AtriCure by 151.6% during the third quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company’s stock worth $6,425,000 after buying an additional 138,046 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in AtriCure by 31.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after acquiring an additional 119,929 shares during the period. Champlain Investment Partners LLC increased its position in AtriCure by 4.3% during the third quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company’s stock worth $78,253,000 after acquiring an additional 115,813 shares during the period. Two Sigma Advisers LP raised its stake in AtriCure by 14.6% during the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock valued at $18,621,000 after purchasing an additional 84,700 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in AtriCure in the 3rd quarter valued at $1,991,000. Institutional investors own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

ATRC has been the topic of several research reports. UBS Group boosted their price objective on shares of AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Needham & Company LLC upped their price target on AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Canaccord Genuity Group boosted their price objective on AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $40.00 target price on shares of AtriCure in a research report on Tuesday, December 17th. Finally, Oppenheimer boosted their price target on shares of AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.38.

AtriCure Stock Up 0.1 %

Shares of NASDAQ ATRC opened at $41.00 on Monday. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The business has a fifty day moving average of $35.19 and a two-hundred day moving average of $30.78. The stock has a market cap of $2.00 billion, a PE ratio of -49.40 and a beta of 1.46.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.